Field report describes posttreatment lesions after tecovirimat therapy for mpox in New York City
What happens after mpox treatment? Doctors describe lingering skin lesions.
A field report from New York City describes posttreatment lesions in mpox patients who received tecovirimat. No sample size, comparator, or …
Doctors in New York City report that some mpox patients developed new skin lesions after finishing antiviral treatment.
Tecovirimat distribution reported during Los Angeles County mpox outbreak
How did Los Angeles County distribute mpox treatment during the outbreak?
A report describes tecovirimat distribution during the 2022-23 mpox outbreak in Los Angeles County. No clinical outcomes, safety data, or co…
A new report details how Los Angeles County distributed the antiviral drug tecovirimat to treat mpox patients during the 2022-23 outbreak.
Case series finds no adverse reaction to tecovirimat in four pregnant persons with mpox
Is the mpox treatment safe for pregnant people? Early data shows no adverse reactions.
A U.S. surveillance case series of mpox in cisgender women reported no adverse reaction to tecovirimat in four treated pregnant persons. No …
Early data on pregnant people treated for mpox shows no adverse reactions to the antiviral drug tecovirimat, offering a small but valuable p…